Chris Adams, an analyst in CBO’s Health Analysis Division, described CBO’s model of new drug development, which is intended to help the Congress understand the effect that legislative proposals would have on the development of new drugs. CBO uses the model to produce alternatives to elasticity estimates presented in the literature.
